文献速递儿科与产科急症消化、代谢与肾脏急症

急诊科近期免疫接种的发热婴儿严重细菌感染风险

Serious bacterial infection risk in recently immunized febrile infants in the emergency department.
PubMed 文献 · Am J Emerg Med · 2024-03-24
一句话结论6–12周近期免疫接种发热婴儿严重细菌感染风险低(3.5%),无侵袭性细菌感染,但尿路感染仍需排查。

本研究为回顾性病历复习,纳入两家美国军队学术急诊科四年内就诊的6–12周、体温≥38°C的发热婴儿508例,其中114例在评估前72小时内接种过疫苗(近期免疫组)。近期免疫组严重细菌感染(SBI)患病率为3.5%(95%CI 1.1–9.3),显著低于非近期免疫组的13.7%(95%CI 10.6–17.6),相对风险0.3(95%CI 0.1–0.7)。近期免疫组无侵袭性细菌感染病例,SBI中除一例肺炎外均为尿路感染。作者认为,近期免疫的6–12周发热婴儿侵袭性细菌感染风险低,但尿路感染风险仍存,应鼓励尿常规和尿培养检查,并与家庭共同决策采取较少侵入性的诊疗方案。

要点

  • 近期免疫组(72小时内接种)SBI患病率3.5%(95%CI 1.1–9.3),非近期免疫组13.7%(95%CI 10.6–17.6),相对风险0.3(95%CI 0.1–0.7)。
  • 近期免疫组无侵袭性细菌感染(IBI)病例,SBI中除一例肺炎外均为尿路感染(UTI)。
  • 唯一非UTI的SBI为一名在免疫后24小时内出现呼吸道症状的婴儿被诊断为肺炎。
  • 作者建议对近期免疫的发热婴儿仍应进行尿常规和尿培养检查以排查UTI。
  • 作者建议与家庭共同决策,对这类患儿采取较少侵入性的诊疗方案。

适用人群与场景

  • 6–12周龄、因发热≥38°C就诊于急诊科的婴儿。
  • 近期免疫(RI)定义为评估前72小时内接种过疫苗;非近期免疫(NRI)定义为该时间段内未接种疫苗。
  • 研究场景为两家美国军队学术急诊科,为期四年。

研究设计与关键结果

  • 研究类型为回顾性病历复习,共纳入508例发热婴儿,其中114例为近期免疫(RI)婴儿。
  • 总体SBI患病率为11.4%(95%CI 8.9–14.6)。
  • NRI组SBI患病率为13.7%(95%CI 10.6–17.6),RI组为3.5%(95%CI 1.1–9.3)。
  • 近期免疫背景下SBI的相对风险为0.3(95%CI 0.1–0.7)。
  • RI组无侵袭性细菌感染(IBI)病例;SBI中除一例肺炎外均为尿路感染(UTI)。
  • 唯一非UTI的SBI为一名在免疫后24小时内出现呼吸道症状的婴儿被诊断为肺炎。

证据类型、等级与局限

  • 证据类型:回顾性病历复习。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,近期免疫的6–12周发热婴儿侵袭性细菌感染(脑膜炎或菌血症)风险低。
  • 作者认为,免疫后24小时内的非侵袭性细菌感染显著低于非近期免疫的发热婴儿。
  • 作者建议,UTI在近期免疫人群中仍是风险,应鼓励进行尿常规和尿培养检查。
  • 作者建议,与家庭共同决策以指导对这些儿童采取较少侵入性的诊疗方案。
  • 作者提出,未来利用大型前瞻性多中心数据登记库的研究将有助于进一步明确近期免疫婴儿中IBI和非IBI的风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVES: Fever following immunizations is a common presenting chiefcomplaint among infants. The 2021 American Academy of Pediatrics (AAP) febrile infant clinical practice guidelines exclude recently immunized (RI) infants. This is a challenge for clinicians in the management of the febrile RI young infant. The objective of this study was to assess the prevalence of SBI in RI febrile young infants between 6 and 12 weeks of age.

METHODS: This was a retrospective chart review of infants 6-12 weeks who presented with a fever ≥38 °C to two U.S. military academic Emergency Departments over a four-year period. Infants were considered recently immunized (RI) if they had received immunizations in the preceding 72 h prior to evaluation and not recently immunized (NRI) if they had not received immunizations during this time period. The primary outcome was prevalence of serious bacterial infection (SBI) further delineated into invasive-bacterial infection (IBI) and non-invasive bacterial infection (non-IBI) based on culture and/or radiograph reports.

RESULTS: Of the 508 febrile infants identified, 114 had received recent immunizations in the preceding 72 h. The overall prevalence of SBI was 11.4% (95% CI = 8.9-14.6) in our study population. The prevalence of SBI in NRI infants was 13.7% (95% CI = 10.6-17.6) compared to 3.5% (95% CI = 1.1-9.3) in RI infants. The relative risk of SBI in the setting of recent immunizations was 0.3 (95% CI = 0.1-0.7). There were no cases of invasive-bacterial infections (IBI) in the RI group with all but one of the SBI being urinary tract infections (UTI). The single non-UTI was a case of pneumonia in an infant who presented with respiratory symptoms within 24 h of immunizations.

CONCLUSION: The risk of IBI (meningitis or bacteremia) in RI infants aged 6 to 12 weeks is low. Non-IBI within the first 24 h following immunization was significantly lower than in febrile NRI infants. UTIs remain a risk in the RI population and investigation with urinalysis and urine culture should be encouraged. Shared decision making with families guide a less invasive approach to the care of these children. Future research utilizing a large prospective multi-center data registry would aid in further defining the risk of both IBI and non-IBI among RI infants.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Casey K, Reilly ER, Biggs K, et al. Serious bacterial infection risk in recently immunized febrile infants in the emergency department. Am J Emerg Med. 2024. PMID: 38583343. doi:10.1016/j.ajem.2024.03.025

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。